文献速递技术与安全CTMRPET

癌症免疫治疗影像学疗效评估的演变:从iRECIST到放射组学与人工智能

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence.
PubMed 文献 · Korean J Radiol · 2022-09-05

本文综述了免疫治疗时代影像学疗效评估的挑战与进展。由于免疫检查点抑制剂及CAR-T等新型药物的应用,假性进展和超进展等非典型反应使传统评估方法受限。文章介绍了免疫相关疗效评估标准、功能/分子影像生物标志物以及放射组学和人工智能等新方法的发展趋势。

要点

  • 免疫治疗可出现假性进展和超进展,阅片时需警惕非典型反应。
  • iRECIST等免疫相关评估标准是当前疗效判读的重要依据。
  • 放射组学和人工智能是新兴的疗效评估研究方向。

核心结论

  • 免疫治疗疗效评估面临假性进展和超进展等非典型反应的挑战,需采用免疫相关评估标准及新方法。

研究设计与样本

  • 本文为综述,检索范围与纳入文献未在摘要中报告。

临床应用与阅片要点

  • 放射科医生应了解免疫治疗药物进展及新疗效评估方法,注意识别假性进展和超进展。

局限性

  • 本文为综述,未报告系统检索策略及纳入文献特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Immunotherapy has revolutionized and opened a new paradigm for cancer treatment. In the era of immunotherapy and molecular targeted therapy, precision medicine has gained emphasis, and an early response assessment is a key element of this approach. Treatment response assessment for immunotherapy is challenging for radiologists because of the rapid development of immunotherapeutic agents, from immune checkpoint inhibitors to chimeric antigen receptor-T cells, with which many radiologists may not be familiar, and the atypical responses to therapy, such as pseudoprogression and hyperprogression. Therefore, new response assessment methods such as immune response assessment, functional/molecular imaging biomarkers, and artificial intelligence (including radiomics and machine learning approaches) have been developed and investigated. Radiologists should be aware of recent trends in immunotherapy development and new response assessment methods.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Kim, Lee, Won, et al. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence. Korean J Radiol. 2022. PMID: 36098343. doi:10.3348/kjr.2022.0225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。